Kiniksa Revenue Per Share vs Current Deferred Revenue Analysis

KNSA Stock

USD 21.28 0.19 0.90%

Kiniksa Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiniksa Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiniksa Pharmaceuticals is a good investment. Please check the relationship between Kiniksa Pharmaceuticals Revenue Per Share and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiniksa Pharmaceuticals Revenue Per Share account and Current Deferred Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Kiniksa Pharmaceuticals' Revenue Per Share and Current Deferred Revenue is -0.75. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Kiniksa Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiniksa Pharmaceuticals' Revenue Per Share and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of Kiniksa Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Revenue Per Share i.e., Kiniksa Pharmaceuticals' Revenue Per Share and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.75

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Kiniksa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiniksa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.The current year's Selling General Administrative is expected to grow to about 125.9 M, whereas Tax Provision is forecasted to decline to (5.8 M).

	2021	2022	2023	2024 (projected)
Interest Income	97K	1.3M	1.1M	1.6M
Net Interest Income	97K	1.3M	1.1M	1.6M

Interest Income Net Interest Income

Kiniksa Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.86	0.94	-0.07	0.95	0.93	-0.5	-0.82	0.8	0.56	0.76	0.49	0.47	0.83	0.95	0.84	0.7	-0.82	0.94	0.92	0.81	-0.5	0.92	0.88	0.84	0.91
Other Current Liab	0.86		0.94	-0.03	0.8	0.82	-0.57	-0.8	0.67	0.62	0.69	0.58	0.3	0.68	0.84	0.75	0.51	-0.64	0.86	0.89	0.84	-0.23	0.8	0.83	0.84	0.76
Total Current Liabilities	0.94	0.94		-0.1	0.9	0.92	-0.55	-0.87	0.81	0.61	0.72	0.55	0.35	0.79	0.95	0.83	0.67	-0.8	0.94	0.96	0.8	-0.41	0.93	0.9	0.93	0.87
Total Stockholder Equity	-0.07	-0.03	-0.1		0.02	-0.16	0.18	0.31	0.05	-0.13	0.39	-0.71	-0.39	-0.29	-0.26	-0.22	-0.25	0.36	-0.27	-0.12	-0.23	0.41	-0.16	0.08	-0.19	-0.23
Net Tangible Assets	0.95	0.8	0.9	0.02		0.92	-0.5	-0.85	0.77	0.57	0.8	0.46	0.37	0.85	0.93	0.82	0.74	-0.86	0.91	0.89	0.77	-0.61	0.96	0.94	0.78	0.92
Property Plant And Equipment Net	0.93	0.82	0.92	-0.16	0.92		-0.42	-0.91	0.66	0.48	0.61	0.56	0.22	0.88	0.98	0.88	0.78	-0.89	0.97	0.96	0.81	-0.61	0.95	0.89	0.87	0.93
Net Debt	-0.5	-0.57	-0.55	0.18	-0.5	-0.42		0.31	-0.72	-0.99	-0.15	-0.26	-0.13	-0.67	-0.46	-0.11	-0.67	0.6	-0.42	-0.37	-0.21	0.45	-0.54	-0.33	-0.45	-0.65
Retained Earnings	-0.82	-0.8	-0.87	0.31	-0.85	-0.91	0.31		-0.5	-0.38	-0.63	-0.78	-0.35	-0.76	-0.94	-0.94	-0.6	0.83	-0.95	-0.93	-0.89	0.58	-0.91	-0.91	-0.81	-0.81
Accounts Payable	0.8	0.67	0.81	0.05	0.77	0.66	-0.72	-0.5		0.74	0.59	0.13	0.38	0.69	0.71	0.45	0.68	-0.69	0.66	0.66	0.37	-0.4	0.76	0.64	0.72	0.75
Cash	0.56	0.62	0.61	-0.13	0.57	0.48	-0.99	-0.38	0.74		0.24	0.28	0.14	0.71	0.52	0.17	0.7	-0.64	0.47	0.44	0.27	-0.48	0.6	0.41	0.49	0.69
Non Current Assets Total	0.76	0.69	0.72	0.39	0.8	0.61	-0.15	-0.63	0.59	0.24		0.23	0.45	0.39	0.64	0.72	0.24	-0.43	0.66	0.71	0.69	-0.13	0.66	0.86	0.54	0.51
Non Currrent Assets Other	0.49	0.58	0.55	-0.71	0.46	0.56	-0.26	-0.78	0.13	0.28	0.23		0.49	0.49	0.66	0.72	0.29	-0.6	0.7	0.62	0.8	-0.45	0.55	0.51	0.49	0.51
Other Assets	0.47	0.3	0.35	-0.39	0.37	0.22	-0.13	-0.35	0.38	0.14	0.45	0.49		0.19	0.39	0.46	0.05	-0.28	0.41	0.29	0.47	-0.13	0.3	0.29	0.26	0.27
Cash And Short Term Investments	0.83	0.68	0.79	-0.29	0.85	0.88	-0.67	-0.76	0.69	0.71	0.39	0.49	0.19		0.87	0.63	0.97	-0.92	0.83	0.76	0.59	-0.77	0.91	0.71	0.77	0.99
Common Stock Total Equity	0.95	0.84	0.95	-0.26	0.93	0.98	-0.46	-0.94	0.71	0.52	0.64	0.66	0.39	0.87		0.91	0.74	-0.91	1.0	0.97	0.85	-0.62	0.96	0.9	0.87	0.93
Common Stock Shares Outstanding	0.84	0.75	0.83	-0.22	0.82	0.88	-0.11	-0.94	0.45	0.17	0.72	0.72	0.46	0.63	0.91		0.44	-0.73	0.94	0.93	0.94	-0.45	0.83	0.89	0.75	0.72
Short Term Investments	0.7	0.51	0.67	-0.25	0.74	0.78	-0.67	-0.6	0.68	0.7	0.24	0.29	0.05	0.97	0.74	0.44		-0.85	0.68	0.62	0.36	-0.76	0.82	0.56	0.7	0.92
Non Current Liabilities Total	-0.82	-0.64	-0.8	0.36	-0.86	-0.89	0.6	0.83	-0.69	-0.64	-0.43	-0.6	-0.28	-0.92	-0.91	-0.73	-0.85		-0.88	-0.82	-0.64	0.88	-0.93	-0.76	-0.69	-0.93
Capital Surpluse	0.94	0.86	0.94	-0.27	0.91	0.97	-0.42	-0.95	0.66	0.47	0.66	0.7	0.41	0.83	1.0	0.94	0.68	-0.88		0.98	0.9	-0.58	0.94	0.9	0.86	0.9
Other Current Assets	0.92	0.89	0.96	-0.12	0.89	0.96	-0.37	-0.93	0.66	0.44	0.71	0.62	0.29	0.76	0.97	0.93	0.62	-0.82	0.98		0.88	-0.48	0.92	0.93	0.88	0.84
Other Stockholder Equity	0.81	0.84	0.8	-0.23	0.77	0.81	-0.21	-0.89	0.37	0.27	0.69	0.8	0.47	0.59	0.85	0.94	0.36	-0.64	0.9	0.88		-0.33	0.74	0.83	0.69	0.68
Total Liab	-0.5	-0.23	-0.41	0.41	-0.61	-0.61	0.45	0.58	-0.4	-0.48	-0.13	-0.45	-0.13	-0.77	-0.62	-0.45	-0.76	0.88	-0.58	-0.48	-0.33		-0.68	-0.47	-0.3	-0.71
Deferred Long Term Liab	0.92	0.8	0.93	-0.16	0.96	0.95	-0.54	-0.91	0.76	0.6	0.66	0.55	0.3	0.91	0.96	0.83	0.82	-0.93	0.94	0.92	0.74	-0.68		0.92	0.86	0.95
Property Plant And Equipment Gross	0.88	0.83	0.9	0.08	0.94	0.89	-0.33	-0.91	0.64	0.41	0.86	0.51	0.29	0.71	0.9	0.89	0.56	-0.76	0.9	0.93	0.83	-0.47	0.92		0.77	0.79
Preferred Stock Total Equity	0.84	0.84	0.93	-0.19	0.78	0.87	-0.45	-0.81	0.72	0.49	0.54	0.49	0.26	0.77	0.87	0.75	0.7	-0.69	0.86	0.88	0.69	-0.3	0.86	0.77		0.83
Total Current Assets	0.91	0.76	0.87	-0.23	0.92	0.93	-0.65	-0.81	0.75	0.69	0.51	0.51	0.27	0.99	0.93	0.72	0.92	-0.93	0.9	0.84	0.68	-0.71	0.95	0.79	0.83

Click cells to compare fundamentals

Kiniksa Pharmaceuticals Account Relationship Matchups

Kiniksa Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	254.5M	349.5M	232.8M	459.7M	526.3M	309.2M
Other Current Liab	25K	27.1M	36.2M	32.6M	50.6M	27.0M
Total Current Liabilities	27.8M	31.8M	44.8M	47.1M	63.7M	38.2M
Total Stockholder Equity	(356.1M)	(517.5M)	(675.4M)	(492.0M)	438.8M	460.8M
Net Tangible Assets	225.4M	311.9M	194.5M	377.9M	434.6M	456.3M
Property Plant And Equipment Net	8.3M	10.6M	8.4M	7.0M	12.7M	7.4M
Net Debt	(44.3M)	(107.1M)	(116.4M)	(116.8M)	(95.7M)	(100.5M)
Retained Earnings	(356.1M)	(517.5M)	(675.4M)	(492.0M)	(478.0M)	(501.8M)
Accounts Payable	5.7M	503K	1.9M	7.9M	8.2M	5.0M
Cash	46.9M	114.0M	122.5M	122.7M	108.0M	126.9M
Non Current Assets Total	12.9M	16.2M	36.4M	216.6M	250.0M	262.5M
Non Currrent Assets Other	210K	5.6M	8.7M	5.8M	827K	785.7K
Other Assets	4.6M	12.2M	8.7M	191.3M	1.0	0.95
Cash And Short Term Investments	233.4M	323.5M	182.2M	190.6M	206.4M	212.4M
Common Stock Total Equity	13K	15K	18K	19K	21.9K	13.4K
Common Stock Shares Outstanding	54.0M	61.8M	68.6M	70.4M	71.9M	57.9M
Short Term Investments	186.5M	209.4M	59.7M	67.9M	98.4M	117.9M
Liabilities And Stockholders Equity	(327.0M)	(479.9M)	(627.6M)	(428.5M)	526.3M	552.6M
Non Current Liabilities Total	1.3M	5.7M	2.9M	16.5M	23.8M	25.0M
Capital Surpluse	581.5M	829.4M	860.5M	888.1M	1.0B	571.2M
Other Current Assets	8.2M	9.8M	13.2M	10.5M	17.5M	9.3M
Other Stockholder Equity	(48K)	829.4M	860.5M	888.1M	916.8M	480.8M
Total Liab	29.1M	37.5M	47.8M	63.5M	87.5M	52.8M
Property Plant And Equipment Gross	8.3M	10.6M	14.3M	13.9M	20.5M	21.5M
Total Current Assets	241.6M	333.2M	196.4M	243.1M	276.3M	234.8M
Accumulated Other Comprehensive Income	33K	(34K)	(66K)	44K	6K	6.3K
Common Stock	13K	15K	18K	19K	20K	14.4K
Property Plant Equipment	8.3M	4.1M	2.8M	1.7M	1.9M	3.7M
Net Invested Capital	225.4M	311.9M	185.0M	396.1M	438.8M	274.5M
Net Working Capital	213.8M	301.4M	151.6M	196.0M	212.6M	216.3M
Other Liab	326K	805K	270K	13.8M	15.9M	16.7M
Retained Earnings Total Equity	(356.1M)	(517.5M)	(675.4M)	(492.0M)	(442.8M)	(465.0M)
Non Current Liabilities Other	326K	5.7M	2.9M	16.5M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:

How To Invest In Kiniksa

Details

Is Kiniksa Stock a good investment?

Details

What is Kiniksa Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

5.5

Earnings Share

(0.12)

Revenue Per Share

5.415

Quarterly Revenue Growth

0.674

Return On Assets

(0.03)

The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kiniksa Revenue Per Share vs Current Deferred Revenue Analysis

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Current Deferred Revenue

Kiniksa Pharmaceuticals fundamental ratios Correlations

Kiniksa Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kiniksa Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Surpluse	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock Total Equity	+ 0.98	Property Plant And Equipment Net
Other Current Assets	+ 0.98	Capital Surpluse
Capital Surpluse	+ 0.97	Property Plant And Equipment Net
Short Term Investments	+ 0.97	Cash And Short Term Investments

Cash	- 0.99	Net Debt
Capital Surpluse	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Common Stock Total Equity	- 0.94	Retained Earnings
Total Current Assets	- 0.93	Non Current Liabilities Total
Deferred Long Term Liab	- 0.93	Non Current Liabilities Total